Physician profile
Michael P Carson
NPI 1235180647
$3,513.58
in general payments reported to CMS, 2019-2025
35 companies · $301 in 2025
The $301 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $592 · 2020: $408 · 2021: $469 · 2022: $349 · 2023: $833 · 2024: $562 · 2025: $301.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,677 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,676.57 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $736.89 | 2020-2025 | Breztri, Airsupra, Lokelma |
| Exact Sciences Corporation | $320.86 | 2023-2025 | Cologuard Collection Kit |
| Novo Nordisk INC | $311.87 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $261.16 | 2021-2024 | Repatha, Otezla |
| Lilly USA, LLC | $231.39 | 2019-2025 | Mounjaro, Jardiance |
| Abbott Laboratories | $196.00 | 2023-2024 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $156.69 | 2019-2022 | |
| Pfizer INC. | $155.60 | 2019-2024 | |
| Gilead Sciences, INC. | $124.70 | 2019 | |
| Sanofi-Aventis U.S. LLC | $114.40 | 2019-2020 | |
| Glaxosmithkline, LLC. | $104.49 | 2019-2023 | Trelegy Ellipta |
| Amarin Pharma, INC. | $96.14 | 2020 | |
| Merck Sharp & Dohme LLC | $94.43 | 2019-2023 | Vaxneuvance, Gardasil 9 |
| Abbvie INC. | $84.60 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $56.20 | 2023-2025 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Melinta Therapeutics, LLC | $55.77 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $49.63 | 2021-2023 | Austedo |
| Sanofi Pasteur INC. | $47.27 | 2019-2023 | |
| Corcept Therapeutics | $37.16 | 2019-2020 | |
| Topcon Healthcare Solutions, INC. | $30.34 | 2020 | |
| Janssen Pharmaceuticals, INC | $29.51 | 2019 | |
| Mannkind Corporation | $27.23 | 2020 | |
| Itamar Medical INC | $23.27 | 2022 | |
| Medtronic, INC. | $19.02 | 2023 | Intellis Adaptivestim |
| Biohaven Pharmaceutical Holding Company LTD. | $15.65 | 2022 | |
| Arbor Pharmaceuticals, INC. | $14.89 | 2021 | |
| Philips North America LLC | $14.78 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $14.37 | 2020 | |
| Optinose US, INC. | $14.33 | 2023 | |
| Biohaven Pharmaceuticals, INC. | $14.10 | 2021 | |
| Cumberland Pharmaceuticals, INC. | $13.56 | 2020 | |
| Ucb, INC. | $12.49 | 2019 | |
| Celgene Corporation | $12.20 | 2019 | |
| Amneal Pharmaceuticals LLC | $11.39 | 2019 | |
| Theratechnologies INC. | $11.20 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Carson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.